Business Wire

Bureau Veritas Accelerates its LEAP | 28 Strategy Execution and Evolves its Executive Committee

18.6.2025 19:00:00 EEST | Business Wire | Press release

Share

Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC) is accelerating the execution of its LEAP | 28 strategy to reach its vision of being the preferred partner for its customers’ excellence and sustainability. Taking LEAP | 28 to the next level, Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment, strengthening its geographical platform with scalable Product Line structures, and optimizing its operations to enhance agility and effectiveness.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618391984/en/

Hinda Gharbi, CEO Bureau Veritas

Since the strategy launch in March 2024, LEAP | 28 strategy execution has progressed steadily in all three pillars – Portfolio, Performance & People - and is now reaching an important stage requiring an evolution of the operating model. The new structure will empower the regions with scalable Product Lines, enabling global offers development, unlocking greater cross-selling opportunities, and driving growth and profitability.

The current six operating geographical Regions will be reorganized into four greater Regions: Americas, Europe, Asia Pacific, Middle East Caspian & Africa. The Product lines will be managed under three executive committee members who will lead: Industrials and Commodities, Urbanization and Assurance, and Consumer Products Services. These groupings at the executive committee level are aligned with customer workflows and market needs.

Considering the company ambition to scale performance programs across all the Regions and Product lines, a Chief Performance Officer and Executive Committee member role will be dedicated to lead the LEAP I 28 performance pillar and the overall optimization of key performance functions of operational excellence & performance, and sales & marketing. This role will drive the design, governance, and overall implementation and monitoring of these programs in coordination with other stakeholders across the organization.

All other Business and Support Functions will remain under their current leaders.

Hinda Gharbi, Chief Executive Officer of Bureau Veritas comments: “By directly connecting Product Lines to a simplified regional structure, we are strengthening our regional expertise and building deeper relations with our customers. This organization will also allow us to create more agility as we accelerate the execution of our LEAP | 28 strategy.

This new organization will leverage scale, benefit from a well-defined structure, thus speeding up decision making, performance impact, and innovation. I fully trust our Bureau Veritas Executive team to mobilize the entire organization to achieve our vision and deliver on our ambition.”

***

The transition period will extend from July 1st to the end of August 2025.
Effective September 1st 2025, the Group Executive Committee will be structured and composed as follows:

Regions:

  • Europe: Executive Vice-President > Vincent Bourdil
  • Middle East Caspian & Africa: Executive Vice-President > Khurram Majeed
  • Asia Pacific: Executive Vice-President > Surachet Tanwongsval
  • Americas: Executive Vice-President to be appointed before year end

Product Lines:

  • Industrials and Commodities: Executive Vice-President > Matthieu Gondallier De Tugny
  • Urbanization and Assurance: Executive Vice-President > Marc Roussel
  • Consumer Products Services: Executive Vice-President > Catherine Chen

Business Functions:

  • Corporate development & sustainability: Executive Vice-President > Juliano Cardoso
  • Chief Performance Officer: Executive Vice-President > Laurent Louail
  • Chief Digital & Innovation Officer: Executive Vice-President DxT (Digital & Technology) > Philipp Karmires

Support Functions:

  • Chief Financial Officer: Executive Vice-President > François Chabas
  • Chief People Officer: Executive Vice-President > Maria Lorente Fraguas
  • Legal affairs & Internal Audit: Executive Vice-President > Beatrice Place-Faget

***

About Bureau Veritas

Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change.
Created in 1828, Bureau Veritas’ 84,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit http://www.bureauveritas.com, and follow us on LinkedIn.

***

Biographies:

Vincent Bourdil, appointed Executive Vice-President, Europe, joined Bureau Veritas in 2016 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Global Business Lines & Performance before becoming Executive Vice-President, Commodities, Industry & Facilities, Southwest Europe.

Khurram Majeed remains Executive Vice-President, Middle East, Caspian & Africa. He is a seasoned industry leader with over 23 years of senior management experience across energy, oil & gas, and other sectors. Khurram joined Bureau Veritas in 2024 as Executive Vice-President, Middle East, Caspian & Africa.

Surachet Tanwongswal remains Executive Vice-President Asia Pacific. He joined Bureau Veritas in 2024 as Executive Vice-President for Commodities, Industry & Facilities in Asia Pacific. Prior to this, Surachet held leadership roles at Ecolab and other global B2B companies.

Matthieu Gondallier de Tugny, appointed Executive Vice-President Industrials and Commodities, joined Bureau Veritas in 1994 and has held various technical, operational, and leadership roles in Marine & Offshore. His most recent role was Executive Vice-President, Marine & Offshore.

Marc Roussel, appointed Executive Vice-President Urbanization and Assurance, joined Bureau Veritas in 2015 and has held multiple leadership roles across the company. His most recent role was Executive Vice-president, Commodities, Industry & Facilities, France.

Catherine Chen remainsExecutive Vice-President Consumer Products Services. She joined Bureau Veritas in 2005 and has held various sales, marketing, and operational leadership roles in Consumer Product Services. Catherine will continue to connect Consumer Products & Technology Product Lines, as Executive Vice-President, Consumer Products Services.

Laurent Louail, appointed Executive Vice-President Chief Performance Officer, joined Bureau Veritas in 1995 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Commodities, Industry & Facilities in Southwest Europe, before becoming Executive Vice-President, Global Business Lines & Performance.

Juliano Cardoso remains Executive Vice-President Corporate Development & Sustainability. He joined Bureau Veritas in 1999 and has held leadership roles across the company. Juliano will continue to lead our corporate development and sustainability efforts in his current role as Executive Vice-President, Corporate Development & Sustainability.

Philipp Karmires remains Executive Vice-President Chief Digital & Innovation Officer. He is a senior executive with over 20 years of experience in digital transformation, enterprise software and product innovation. Philipp joined Bureau Veritas in 2024 and will continue to lead the DxT (Digital & Technology) function as Executive Vice-President, Chief Digital & Innovation Officer.

François Chabas remains Executive Vice-President Chief Financial Officer. He joined Bureau Veritas in 2003, holding finance roles with increasing responsibility before becoming Chief Financial Officer in 2014. François will continue to lead the finance function as Executive Vice-President, Finance.

Maria Lorente Fraguas remainsExecutive Vice-President Chief People Officer. She joined Bureau Veritas in 2024 after holding senior operational and human resources roles in international companies across multiple countries. Maria will continue to lead the people function as Executive Vice-President, Chief People Officer.

Béatrice Place-Faget remainsExecutive Vice-President Legal & Internal Audit. She joined Bureau Veritas in 2020 after serving as general counsel for other companies in France. Béatrice will continue to lead the legal and compliance function as Executive Vice-President, Legal affairs & Internal Audit.

Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250618391984/en/

Contacts

ANALYST/INVESTOR CONTACTS
Laurent Brunelle
+33 (0)1 55 24 76 09
laurent.brunelle@bureauveritas.com

Colin Verbrugghe
+33 (0)1 55 24 77 80
colin.verbrugghe@bureauveritas.com

MEDIA
Anette Rey
+33 (0)6 69 79 84 88
anette.rey@bureauveritas.com

Martin Bovo
+33 (0) 6 14 46 79 94
martin.bovo@bureauveritas.com

Karine Ansart
karine.ansart@bureauveritas.com

Inès Lagoutte
ines.lagoutte@bureauveritas.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 08:03:00 EEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye